Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN 8 5 PH6 versus TRAVASOL 10 W O ELECTROLYTES.
Head-to-head clinical analysis: AMINOSYN 8 5 PH6 versus TRAVASOL 10 W O ELECTROLYTES.
AMINOSYN 8.5% (PH6) vs TRAVASOL 10% W/O ELECTROLYTES
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn 8.5% (pH 6) provides a mixture of essential and nonessential amino acids for protein synthesis and nitrogen balance maintenance in patients unable to tolerate oral or enteral nutrition.
Travasol 10% w/o electrolytes is a parenteral nutrition solution containing essential and non-essential amino acids. The amino acids provide substrates for protein synthesis, thereby supporting tissue repair, growth, and maintenance. The solution also provides a source of nitrogen and caloric replacement.
1-1.5 g amino acids/kg/day intravenously, typically 500 mL of a 8.5% solution (42.5 g amino acids) infused over 8-24 hours.
10% amino acid solution administered intravenously via central line at 0.5-1.0 g amino acids/kg/day, not to exceed 2.5 g/kg/day; typical infusion rate 50-125 mL/hr.
None Documented
None Documented
Not applicable as a fixed value; elimination half-life of individual amino acids varies (minutes to hours) and is dependent on metabolic demand and renal function.
The terminal elimination half-life of infused amino acids is approximately 1-2 hours, reflecting rapid metabolism and clearance. Clinical context: Steady state is achieved within 1-2 hours of continuous infusion.
Primarily renal; elimination depends on metabolic utilization. Unused amino acids are deaminated and excreted as urea in urine (over 90%). Fecal elimination is negligible.
Amino acids are primarily metabolized; nitrogen is excreted renally as urea (∼85-90%), with small amounts in feces (∼5%) and minimal biliary elimination. Electrolytes are excreted renally, with excretion proportional to intake and renal function.
Category C
Category C
Amino Acid Solution
Amino Acid Solution